Biophan Announces William L. Holman, MD, Has Joined The MYOTECH Scientific Advisory Board.ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BIPH BIPH Bogomoletz Institute of Physiology (National Academy of Sciences; Ukraine) ; FWB (Fixed Wireless Broadband) See fixed wireless. : BTN BTN In currencies, this is the abbreviation for the Bhutan Ngultrum. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ), a developer of next-generation medical technology, today announced that William L. Holman, MD, has joined the MYOTECH Scientific Advisory Board. MYOTECH and Biophan are co-developing the MYO-VAD[TM], a unique cardiac recovery system designed to treat many types of heart failure. Jeffrey L. Helfer, President of Biophan's Cardiovascular Division stated, "Dr. Holman's extensive knowledge and experience in cardiothoracic surgery Cardiothoracic surgery is the field of medicine involved in the surgical treatment of diseases affecting organs inside the thorax (the chest). Generally treatment of conditions of the heart (heart disease) and lungs (lung disease). will be invaluable to the further development and clinical evaluation clinical evaluation Medtalk An evaluation of whether a Pt has symptoms of a disease, is responding to treatment, or is having adverse reactions to therapy of the MYO-VAD." The MYO-VAD is a cardiac recovery system that can be installed around an arrested or weak heart in under three minutes "Three Minutes" is the 46th episode of Lost. It is the twenty-second episode of the second season. The episode was directed by Stephen Williams, and written by Edward Kitsis and Adam Horowitz. It first aired on May 17, 2006 on ABC. , restoring cardiac output cardiac output n. Abbr. CO The volume of blood pumped from the right or left ventricle in one minute. It is equal to the stroke volume multiplied by the heart rate. in both acute failure situations and for long-term support. Incorporating a pneumatically activated liner, the MYO-VAD operates by compressing and expanding bi-directionally, providing the energy that allows the heart to restore the output of blood to normal, life sustaining levels. Since it is not blood-contacting, unlike virtually all existing cardiac assist devices, the MYO-VAD has the potential to avoid complications, including clotting and stroke, bleeding, and infection. The MYO-VAD represents a major advance over traditional methods of cardiac support. Dr. Holman has nearly twenty years TWENTY YEARS. The lapse of twenty years raises a presumption of certain facts, and after such a time, the party against whom the presumption has been raised, will be required to prove a negative to establish his rights. 2. experience in Cardiothoracic Surgery. He has been Chief of Cardiothoracic Surgery at the Birmingham VA Medical Center since 1988. Dr. Holman said, "The MYO-VAD technology for circulatory assistance has important advantages over other devices, and has the potential to improve survival in a challenging patient population. It is a pleasure to be a member of the MYOTECH Scientific Advisory Board." Biophan Technologies, Inc. holds a 42% interest in MYOTECH with rights to acquire a majority position, and is leading MYOTECH's business development. Dr. Holman is also currently a Professor in the Division of Cardiothoracic Surgery at the University of Alabama at Birmingham UAB began in 1936 as the Birmingham Extension Center of the University of Alabama. Because of the rapid growth of the Birmingham area, it was decided that an extension program for students who had difficulties which prevented them from studying in Tuscaloosa was needed. (since 1998), where he is also Senior Scientist at the Center for Outcomes and Effectiveness Research and Education (since 2001), and Senior Scientist at the University's Center for Aging (since 2003). He has served as a member and/or advisor to numerous boards and institutions. Dr. Holman received his undergraduate training at Williams College in Williamstown, MA and his medical studies were completed at Cornell University Medical College in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Information on the MYO-VAD can be found at www.biophan.com. About Biophan Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company licenses its technologies which improve the MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. safety and image compatibility of medical devices to leading device manufacturers. In addition, the Company is commercializing the MYOTECH MYO-VAD[TM], a new, cardiac recovery system which has significant potential to improve the treatment of many forms of heart disease. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange Frankfurt Stock Exchange The largest of Germany's eight securities exchanges, operated by Deutsche Borse AS. under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com. Cautionary Statement Regarding Forward-Looking Statements Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion